I.v. tenoxicam for analgesia during caesarean section

Area of Science:

• Anesthesiology
• Pharmacology
• Obstetrics

Background:

• Postoperative pain management is crucial following Caesarean section.
• Minimizing hemodynamic variability during anesthesia induction is important for patient safety.
• Opioid consumption can lead to adverse effects.

Purpose of the Study:

• To evaluate the analgesic efficacy of tenoxicam in patients undergoing Caesarean section.
• To assess the impact of tenoxicam on postoperative opioid requirements.
• To determine the effect of tenoxicam on hemodynamic stability and maternal/infant outcomes.

Main Methods:

• A randomized controlled trial involving 50 patients undergoing elective Caesarean section.
• A single intravenous dose of tenoxicam (20 mg) administered 10 minutes before anesthesia induction in the study group.
• Control group received standard care without tenoxicam; nalbuphine consumption, pain scores, and hemodynamic parameters were monitored.

Main Results:

• Tenoxicam reduced 24-hour nalbuphine consumption by 50% and increased the time to first analgesia request from 25 to 110 minutes.
• Patients receiving tenoxicam reported significantly less pain and sedation postoperatively.
• Hemodynamic variability after intubation was shorter in the tenoxicam group; no significant differences in nausea, vomiting, or infant well-being were observed.

Conclusions:

• A single intravenous dose of tenoxicam is effective in reducing postoperative opioid consumption and pain after Caesarean section.
• Tenoxicam pretreatment helps minimize hemodynamic variability during anesthesia induction and delivery.
• Tenoxicam demonstrates a favorable safety profile in this obstetric population, with no adverse effects on infants.